Company intelligence / Profile preview
HEDROS Biotechnology
San Diego, California, United Stateshedros.bio ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Hedros Biotechnology is a San Diego-based biotechnology company specializing in the development of oral small molecule inhibitors targeting the IL-17 pathway. The company was established to address the need for oral alternatives to injectable biologic therapies for chronic inflammatory conditions, particularly in dermatology. Its lead programs focus on blocking IL-17 signaling to treat diseases such as psoriasis. In 2021, Hedros Biotechnology was acquired by LEO Pharma, a leader in medical dermatology, to enhance its portfolio of oral treatments for skin diseases. The acquisition allowed LEO Pharma to integrate Hedros's innovative small molecule research into its global R&D pipeline.
- Therapeutic areas
- ImmunologyDermatology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on HEDROS Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HEDROS Biotechnology.